[The pulmonary vasodilatory effect of inhaled prostacyclin and milrinone in heart].
This paper examined the effect of inhaled prostaglandin I2 at a dose of 5-10 microgram/ml on vascular resistance in the treatment of pulmonary hypertension, for its local benefits and lack of effect on systemic vascular resistances. The treatment was also combined with inhaled milrinone at a dose of 1 mg/ml, given that the mechanisms of action of the two drugs are different and possibly complementary. Inhaling both drugs might be an effective approach to treating pulmonary hypertension.
Ricksten
S
S
Department of Cardiothoracic Anaesthesia and Intensive Care, Sahlgrenska University Hospital, Gotemburgo, Suecia.
D000208:Acute Disease; D000280:Administration, Inhalation; D006348:Cardiac Surgical Procedures; D000242:Cyclic AMP / Q000502:physiology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy*; D020105:Milrinone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D011652:Pulmonary Circulation / Q000187:drug effects*; D015290:Second Messenger Systems / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018497:Ventricular Dysfunction, Right / Q000517:prevention & control
D014665:Vasodilator Agents; D011464:Epoprostenol; D000242:Cyclic AMP; D020105:Milrinone